BLUE-PLANET
7.9.2021 18:13:07 CEST | Business Wire | Press release
China’s Blue Planet Science-Fiction Film Festival (BPSFF), launched by Xinhuanet, was highlighted in the “Focus on China” event at the 78th Venice International Film Festival (VIFF) on Sept. 5. The event, held through a combination of online and offline activities, featured notable guests from Italy and China and focused on the cultivation of young film & TV talent and international cooperation amidst the pandemic.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210907005705/en/
"At this special time, this kind of cultural exchange between China and Italy carries important symbolism. Practical challenges have not hindered our cultural cooperation," said Francesco Rutelli, president of the Italian Association of Film, Audio-visual and Digital Industry (ANICA), a co-host of the “Focus on China” event.
"This year is the 6th edition of the VIFF's 'Focus on China' event. It has been a long journey and we will continue to promote such exchanges," said Rutelli. "Beijing will soon host the Winter Olympics and Milan and Cortina d'Ampezzo in Italy will host the next one – a kind of 'relay' that connects China and Italy."
At the event, Wang Zhenzheng, chief content officer of the BPSFF, gave a presentation on the theme “Symbiosis - Talent cultivation, Industry links, and Imagination flow.” After two years of development, BPSFF has become China's largest sci-fi film festival – as well as the largest platform for sci-fi film professionals and filmmaking talent; the largest platform for sci-fi content, and a key platform for cross-border exchange in science and technology.
Since the first edition in 2019, the BPSFF has attracted over 500 sci-fi films from more than 30 countries and regions around the world. It has become a platform for new exploration to showcase the vision of young sci-fi filmmakers from China and around the world.
"This November, the 3rd Blue Planet Science-Fiction Film Festival will be held under the theme of 'Migrating' – allowing fresh ideas and imagination to flow around the world and add a special 'New Species' section to showcase sci-fi for young people," said Wang.
This year’s “Focus on China” event also featured the BPSFF, a special market screening session at VIFF of selected Chinese sci-fi films, including Newborns Lawyer directed by Chen Yuhang, Nihilism by Deng Di, A short Dream by Shu Haolun, The Castle up Cloud by Luo Bofan.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210907005705/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Provides Progress Update Regarding RelabotulinumtoxinA Regulatory Submission in the United States1.7.2026 07:00:00 CEST | Press release
Galderma received a Complete Response Letter from the FDA with comments related to observations during manufacturing site inspection and analytical method optimization Relfydess is approved in 33 markets and already launched in more than 20, including across Europe, the Middle East and Australia, with an encouraging early launch trajectory supported by positive healthcare professional feedback Regulatory filings in other territories are ongoing and remain on track Ad hoc announcement pursuant to Art. 53 LR Galderma (SIX: GALD) today provided progress updates regarding the regulatory review of its pending Biologics License Application (“BLA”) for RelabotulinumtoxinA with the U.S. Food and Drug Administration (“FDA”). The Company has received a Complete Response Letter (CRL) from the FDA with comments related to observations during manufacturing site inspection and analytical method optimization. As part of its review, the FDA conducted a Pre-License Inspection (PLI) of Galderma’s manufa
EVE Energy Showcases All-Scenario Energy Storage Solutions at The Smarter E Europe 20261.7.2026 03:45:00 CEST | Press release
EVE Energy unveiled its Mr. Big Family series, a 6.9+ MWh energy storage system, and all-scenario energy storage solutions at Intersolar Europe in Munich. Drawing on traceable large-cell technology, proven large-scale energy storage project delivery experience, and global delivery capabilities, the company is addressing Europe's diverse energy storage requirements across utility-scale, commercial & industrial (C&I ), and data center segments. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260630889717/en/ EVE Energy showcases its Mr. Giant 3.0 6.9+ MWh energy storage system at The Smarter E Europe 2026 in Munich, Germany Advancing Large-Cell Technology with Global Project Validation As one of the first companies to focus on large-capacity energy storage cells, EVE Energy has iteratively upgraded its cell platform from 560 Ah and 628 Ah to 702 Ah, adhering to a stacking process route throughout. At the exhibition, the Mr. Gia
Bending Spoons S.p.A. announces pricing of initial public offering1.7.2026 01:56:00 CEST | Press release
Bending Spoons S.p.A. (“Bending Spoons”), a leading technology company, today announces the pricing of its initial public offering (“IPO”) at $29.00 per share. A total of 57,971,015 ordinary shares are being offered, of which 34,398,640 shares are being offered by Bending Spoons and 23,572,375 shares are being offered by certain selling shareholders (the “Selling Shareholders”). Bending Spoons will not receive any proceeds from any sale of shares by the Selling Shareholders. The shares are expected to begin trading on the Nasdaq Global Select Market under the ticker symbol “BSP” on July 1, 2026. The offering is expected to close on July 2, 2026, subject to customary closing conditions. In addition, Bending Spoons and the Selling Shareholders granted the underwriters an option to purchase up to an additional 5,244,026 ordinary shares from Bending Spoons and up to an additional 3,451,626 ordinary shares from the Selling Shareholders at the initial public offering price, less underwriting
FDA Issues Modified Risk Tobacco Product Orders for 20 ZYN Nicotine Pouch Products30.6.2026 18:19:00 CEST | Press release
FDA’s decision makes ZYN the first nicotine pouch product to receive MRTP orders authorizing reduced-risk claims versus cigarettes Philip Morris International Inc. (PMI) (NYSE: PM) today announced that the U.S. Food and Drug Administration (FDA) issued Modified Risk Tobacco Product (MRTP) orders for 20 variants of ZYN nicotine pouch products. These are the first MRTP orders granted for nicotine pouches, allowing PMI U.S. to market the following claim for the authorized ZYN products: “Using ZYN instead of cigarettes puts you at a lower risk of mouth cancer, heart disease, lung cancer, stroke, emphysema, and chronic bronchitis.” “FDA’s decision is an important moment for the more than 45 million legal-age nicotine consumers in America,” saidStacey Kennedy, PMI U.S. CEO. “Today’s news ensures these adultshave access to accurate, science-based information, including FDA-authorized evidence that switching from cigarettes to ZYN reduces the risk of smoking-related diseases like heart disease
Caidya Announces Strategic Combination with Simbec-Orion Bridging Early Scientific Insight and Global Clinical Execution30.6.2026 17:00:00 CEST | Press release
Caidya today announced a strategic combination with Simbec-Orion designed to close the divide between early scientific insight and global clinical execution. The combination of Caidya and Simbec-Orion creates a differentiated specialty clinical CRO platform that enables programs to scale, maintaining focus, speed, and accountability. The strategic combination brings together complementary strengths to create a more complete development partner for innovative biopharma companies. With established operations across Europe, the Americas, APAC, and China, the combined organization provides meaningful expertise and execution capabilities in the regions that matter most. Simbec-Orion brings early-phase clinical pharmacology capabilities alongside deep therapeutic expertise for later stage complex oncology and rare disease trials, helping sponsors shape critical decisions early in the development lifecycle. Together, the organizations strengthen their ability to support complex, cross-border
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom